Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Mantle-Cell 9Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Glioblastoma 1DLBCL 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1Advanced Haematological Malignancies 1

Interventions

Rituximab 173Cyclophosphamide 156Vincristine 72fludarabine phosphate 71Etoposide 68Doxorubicin 68Prednisone 66Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma × acalabrutinib × Clear all
NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acerta Pharma BV

Phase 2 Completed
48 enrolled 12 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Acerta Pharma BV

Phase 1 Completed
21 enrolled 11 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡